アラバマ州における大うつ病性障害の臨床試験
アラバマ州内の拠点で、大うつ病性障害に関する15件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/25更新 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
被験者募集中第3相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/08更新 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
被験者募集中
22歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/08/14更新 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/08/03更新 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/24更新 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
被験者募集中健康なボランティア歓迎
10歳〜24歳 · 全性別 · 2026/07/13更新 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/06/15更新 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
被験者募集中観察研究健康なボランティア歓迎
18歳〜60歳 · 全性別 · 2026/03/30更新 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
被験者募集中
25歳〜50歳 · 全性別 · 2026/03/03更新 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/01/20更新 · NCT06633016ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。